Get Ahead of the Next Generation of Conjugates with New Data on Dual-Payload, Pathway-Directed, Degrader & Bispecific Programs from the Teams Taking Them to the Clinic
Novel conjugates have moved from emerging idea to strategic priority. Dual-payload and alternative-mechanism programs are reaching the clinic, the first bispecific ADC has reached the market, and big pharma is backing the space with a wave of deals and acquisitions.
The 6th Novel Conjugates Summit is the only industry-led forum dedicated entirely to novel payloads and targeting formats. There is no traditional ADC content here, just the data, mechanisms and translational lessons from the programs making the most progress.
That shift is changing what discovery teams need from a conference. Classical Topo1 and MMAE payloads face resistance, narrow therapeutic windows and a crowded field, so the questions are now practical: which payload mechanisms justify the added complexity, how to pair payloads and control PK, ratio and tolerability, how to choose between bispecific, biparatopic, peptide and fragment formats, and what preclinical evidence shows a program is ready for IND.
In a room of 80+ discovery, bioconjugation and R&D leaders from big pharma, traditional ADC & novel conjugate biotechs, the focus is depth over volume: science-led sessions, candid discussion of what is working and what is not, and time to connect with everyone attending.
Across a workshop day dedicated to designing novel conjugates with clinical intent, and two single-track conference days which spotlight new data on dual-payload, pathway-directed, degrader and bispecific conjugates, a look at conjugates beyond oncology, and networking built so that no one in the room is out of reach. If your next program depends on what comes after Topo1 and MMAE, this is where your team needs to be in 2027.
Speakers
Sorry, we couldn't find any posts. Please try a different search.
Attending Companies Include: